Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma Science reported consolidated revenue of Rs. 50,094 million for FY2026, up 8.3% from Rs. 46,241 million in FY2025. Profit after tax from continuing operations grew 40.3% to Rs. 5,745 million, while total comprehensive income stood at Rs. 6,185 million. The Board recommended a final dividend of Rs. 5 per share (50% payout). The auditor issued an unmodified (clean) opinion. Exceptional items of Rs. 268 million included product recall expenses (Rs. 229 million) and asset impairments. During the year, the company divested Strides CIS Limited and dissolved Apollo Life Sciences, while also acquiring the remaining 50% stake in Neviton Softech Private Limited.
Strong profitability growth with PAT up 40% and positive cash flows of Rs. 7,025 million signal operational strength. The clean audit opinion and dividend payout are positive for shareholders, though ongoing product recall provisions warrant monitoring.